SBTX Silverback Therapeutics

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Cantor Global Healthcare Conference being held September 17-19, 2024 in New York City.

Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Tuesday, September 17, 2024, at 9:10 a.m. ET. Company management will also participate in one-on-one meetings with investors.

A live webcast of the fireside chat will be available and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy in the EU) (previously referred to as ARS-1), an epinephrine nasal spray for patients with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit .

ARS Investor Contacts:

Justin Chakma

ARS Pharmaceuticals

ARS Media Contact:

Christy Curran

Sam Brown Inc.



EN
10/09/2024

Underlying

SBTXSilverback Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silverback Therapeutics

 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financia...

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS ...

March 9, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Four...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 fi...

February 23, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clini...

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting -Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients’ dislike of needle-based administration, the value of a nasal option increased by mor...

February 10, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

California K-12 Schools Now Eligible for neffyinSchools Program, Offer...

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use California joins 23 other states eligible to receive free neffy® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that California, the state where ARS Pharma is headquartered, is now eligible for its nef...

January 21, 2026 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

neffy® (epinephrine nasal spray) Approved in China as the First and On...

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China under the trade name 优敏速®, expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharma...

December 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch